Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2025-12-25 @ 3:56 AM
NCT ID:
NCT07202702
Eligibility Criteria:
Inclusion Criteria:
* Between ages 18 and 45 years old (to avoid any changes in the developing brain, or with aging).
* Answer 'no' to questions 2 through 16 on the tDCS checklist as these factors can increase likelihood of adverse events with tDCS
* No neurological damage, disease, or dysfunction (nerve damage, chronic pain disorders, diabetic neuropathy) that affect the upper limbs.
* No significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study
Exclusion Criteria:
* • Currently prescribed and taking stimulant medication (Adderall, Ritalin, Vyvanse, etc.)
* Consumption of over-the-counter stimulants such as caffeine or nicotine (coffee, soda, supplements, energy drinks, tobacco products, or other nicotine containing products such as gum, vape pens, etc...) 12 hours prior to entering the lab on the day of testing as this can directly affect cortical excitability. If a subject takes any of these substances 12 hours prior to session 1 they will be asked to reschedule for a later date.
* Have played a real stringed instrument in the last 12 months (e.g. guitar, bass, violin)
* Have played the videogame "Guitar Hero" on a traditional guitar controller in the last 12 months.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
45 Years
Study:
NCT07202702
Study Brief:
Protocol Section:
NCT07202702